Auhtors: Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI
PMID: 33923028 PMCID: PMC8123278 DOI: 10.3390/molecules26092506
Abstract
Melatonin is a pleotropic molecule with numerous biological activities. Epidemiological and experimental studies have documented that melatonin could inhibit different types of cancer in vitro and in vivo. Results showed the involvement of melatonin in different anticancer mechanisms including apoptosis induction, cell proliferation inhibition, reduction in tumor growth and metastases, reduction in the side effects associated with chemotherapy and radiotherapy, decreasing drug resistance in cancer therapy, and augmentation of the therapeutic effects of conventional anticancer therapies. Clinical trials revealed that melatonin is an effective adjuvant drug to all conventional therapies. This review summarized melatonin biosynthesis, availability from natural sources, metabolism, bioavailability, anticancer mechanisms of melatonin, its use in clinical trials, and pharmaceutical formulation. Studies discussed in this review will provide a solid foundation for researchers and physicians to design and develop new therapies to treat and prevent cancer using melatonin.
Keywords: anticancer; cancer therapy; hormonal therapy; phytomelatonin; pineal gland.
Source: https://pubmed.ncbi.nlm.nih.gov/33923028/
Archive: https://archive.is/c5Doi
